中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (18): 3401-3404.doi: 10.3969/j.issn.1673-8225.2011.18.042

• 器官移植临床实践 clinical practice of organ transplantation • 上一篇    下一篇

肾移植后急性排异反应12例

龙  伟,杨广庭,姜  伟,刘彦斌,裴向克,白玉梅,托  娅,张春媛   

  1. 解放军第281医院,河北省秦皇岛市  066100
  • 收稿日期:2011-01-18 修回日期:2011-02-22 出版日期:2011-04-30 发布日期:2011-04-30
  • 作者简介:龙伟,男,1971年生,湖南省岳阳市人,汉族,1997年解放军第二军医大学毕业,主治医师,主要从事肾移植临床及研究工作。 longwei0000@163.com

Acute rejection following kidney transplantation in 12 cases

Long Wei, Yang Guang-ting, Jiang Wei, Liu Yan-bin, Pei Xiang-ke, Bai Yu-mei, Tuo Ya, Zhang Chun-yuan   

  1. The 281 Hospital of Chinese PLA, Qinhuangdao  066100, Hebei Province, China
  • Received:2011-01-18 Revised:2011-02-22 Online:2011-04-30 Published:2011-04-30
  • About author:Long Wei, Attending physician, the 281 Hospital of Chinese PLA, Qinhuangdao 066100, Hebei Province, China longwei0000@163.com

摘要:

背景:同种异体肾移植后发生的急性排斥反应是移植肾功能减退和最终移植肾丧失的最主要原因之一。有效预防和早期发现与治疗急性排异反应是关系到肾脏移植患者能否长期存活的重要问题。
目的:总结肾移植后1个月内急性排异反应患者治疗过程中免疫抑制剂的应用体会。
方法:选择首次肾移植患者12例,移植后采用霉酚酸酯+环孢素A+甲泼尼龙三联预防排异反应。当肾移植后3~30 d内出现尿量减少、移植肾区胀痛不适、血肌酐升高、尿蛋白增加等不同临床表现,确诊为肾移植后急性排斥反应时,先选用甲强龙500 mg/d静脉滴注,连续3 d。然后改甲泼尼龙24 mg口服1次/d,每5~7 d递减4 mg,至8 mg/d维持。
结果与结论:12例患者成功逆转,其中6例甲强龙冲击疗法成功;不能逆转者选用抗胸腺细胞球蛋白或CD3治疗。4例经抗胸腺细胞球蛋白治疗患者中1例8h内尿量迅速增加,2例24 h内尿量迅速增加,1例72 h后尿量迅速增加;1例选用CD3治疗48 h内尿量迅速增加;1例将环孢素转换为他克莫司治疗,同时服用霉酚酸酯胶囊和甲泼尼龙片。经以上治疗12例患者肾功能逐渐恢复。提示肾移植后早期发现、早期诊断、及时治疗是急性排异反应成功逆转的关键。

关键词: 急性排异反应, 肾移植, 免疫抑制, 甲强龙, 冲击疗法

Abstract:

BACKGROUND: After the allogeneic kidney transplant operation, acute rejection is one of the most important reasons of transplant kidney hypofunction and eventually defunctionalization. So effective prevention, early diagnosis and acute rejection therapy are important things which relate closely to how long the patient can live.
OBJECTIVE: To summarize the experience of application of immunosuppressive on patients with acute rejection in one month after kidney transplantation.
METHODS: A total of 12 kidney transplantation patients were selected, who are all the first time to do the transplant. After the kidney transplantation, using mycophenolate mofetil capsules, cyclosporine A and methylprednisolone as triple regimen to prevent rejection. During 3 to 30 days after operations, the 12 patients had different clinical manifestation, such as hypourocrinia, kidney transplanted area swollen, serum creatinine increase, urine protein increase, instituted as acute rejection after renal transplantation. First, the patients were treated with methylprednisolone pulse therapy: 5mg/d (d1-3), intravenous drip. Then, taking it orally instead, 24 mg/d, decreasing by 4 mg every 5-7 d, until 8 mg/d.
RESULTS AND CONCLUSION: 12 cases reversed successfully, including 6 cases which reversed by methylprednisolone. Those unable to reverse were treated with Antithymocyte Globulin (ATG) or CD3. In 1 of 4 cases with ATG, urinary output increased rapidly within 8 hours, 2 cases within 24 hours and 1 case within 72 hours. One case with CD3, patient’s urinary output rose quickly within 48 hours. One case used tacrolimus instead of cyclosporine A, at the same time took mycophenolate mofetil capsules and methylprednisolone. After the above treatments, kidney function in all 12 cases recovered gradually. The results suggested that, for patients with acute rejection after kidney transplantation, early detection, diagnosis and timely therapy is the key to reversal successfully.

中图分类号: